The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy
- 14 June 2001
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 39 (1-2) , 195-201
- https://doi.org/10.1016/s1040-8428(01)00108-1
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomasBlood, 2000
- Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experienceAnnals of Hematology, 2000
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999
- Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.Journal of Clinical Oncology, 1998
- Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22Cancer Immunology, Immunotherapy, 1997
- Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomasThe Lancet, 1995
- Internalization and intracellular processing of an anti B‐cell lymphoma monoclonal antibody, ll2International Journal of Cancer, 1994
- Initial clinical results with technetium-99m-labeled ll2 monoclonal antibody fragment in the radioimmunodetection of b-cell lymphomasCancer, 1994
- Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.Journal of Clinical Oncology, 1991